Bruceine A is a natural compound found in the plant species Brucea javanica, commonly known as the Java brucea fruit. It has gained attention for its potential therapeutic properties in various diseases, including cancer, inflammation, and malaria. Bruceine A targets several signaling pathways involved in these diseases, making it a promising candidate for the development of novel therapeutics.
Chemical name:
(20S,21S)-20,21-Dihydrobruceine A
Molecular formula:
C28H40N2O4
Formula weight:
472.64 g/mol
CAS No:
25514-31-2
Top ten keywords from Google and Synonyms:
Health benefits of this product:
Bruceine A has shown potential health benefits in the treatment of various diseases, including cancer, inflammation, and malaria. Studies have shown that Bruceine A can induce apoptotic cell death in cancer cells, exhibit antitumor activity, and reduce inflammation. Additionally, Bruceine A has been found to enhance the efficacy of artemisinin-based combination therapy, the standard of care for malaria treatment.
Potential effects:
Bruceine A has several potential effects on the body. One of the primary mechanisms is through the induction of apoptotic cell death in cancer cells by activating several signaling pathways involved in cell death. Bruceine A also exhibits antitumor activity by inhibiting the growth and proliferation of cancer cells. Additionally, Bruceine A reduces inflammation by inhibiting the expression of pro-inflammatory cytokines. Lastly, Bruceine A enhances the efficacy of artemisinin-based combination therapy, reducing the risk of malaria treatment failure.
Product mechanism:
Bruceine A works by targeting several signaling pathways involved in cancer, inflammation, and malaria. One of the primary mechanisms is through the induction of apoptotic cell death in cancer cells by activating several signaling pathways involved in cell death. In cancer, Bruceine A inhibits the growth and proliferation of cancer cells by blocking several signaling pathways involved in cell cycle progression. Additionally, Bruceine A reduces inflammation by inhibiting the expression of pro-inflammatory cytokines. Lastly, Bruceine A enhances the efficacy of artemisinin-based combination therapy by increasing the uptake and killing of malaria parasites.
Safety:
Bruceine A has been found to be generally safe in preclinical studies. However, further research is needed to determine the safety and efficacy of Bruceine A in humans.
Side effects:
Currently, there is limited information available regarding the potential side effects of Bruceine A. Some studies have reported mild adverse events such as gastrointestinal disturbances and headache. Further research is needed to determine the full extent of the drug's side effects.
Dosing information:
There are currently no established guidelines for the dosing of Bruceine A in humans. Doses used in preclinical studies have ranged from 0.5 mg/kg to 10 mg/kg. Further research is needed to determine the optimal dosing regimen for Bruceine A in humans.
Conclusion:
Bruceine A is a natural compound with potential therapeutic properties in the treatment of various diseases, including cancer, inflammation, and malaria. The drug has been shown to target several signaling pathways involved in these diseases, making it a promising candidate for the development of novel therapeutics. However, its safety and efficacy in humans need to be further studied. Overall, Bruceine A shows great promise as a targeted therapy for various diseases, and may provide valuable insights into the development of future treatments for cancer, inflammation, and malaria
